

Company Overview



■ Manufacturer of consumables and equipment for mining and industry, for X-Ray Fluorescence (XRF) analysis — a powerful long-established analytical technique, vital to the discovery, evaluation, qualification and production of most metals and control of material manufacturing processes

X-Ray Flux and chemicals





Platinum Labware and Precision Platinum Products




Specialised furnaces and laboratory equipment



The XRF Analysis Process





The glass disk is presented into an x-ray spectrometer for analysis

The sample dust is then fused into a glass bead using **XRF Scientific's products**

Our Products



Products

Service

Applications Support

Laboratory







Industry



Materials:

- Cement
- Steel
- Glass
- Ceramics
- Research
- Education



Mining



Sample sources:

- Production
- Shipping
- Exploration

Minerals:

- Iron ore
- Nickel
- Copper
- Aluminium
- Bauxite
- Manganese
- Uranium
- Lithium
- Mineral sands
- Commercial labs

Precious Metals Expansion





New Germany Office 25+ years experience in sales and production of platinum products August 2016



New Melbourne Factory 2100 sqm owned by XRFS, \$1.8m cost plus \$0.9m improvements November 2016



Production Improvements
Enhance existing products, improve core production methods, expand existing product lines
Ongoing since 2016



New Equipment
Investments made to expand
production capability and our
product range
1H18

Expanding in Europe

Sale of fusion products into new European countries **Ongoing**









New Product Developments

New additional Precision Platinum components into significantly larger industries than labware markets e.g. aerospace, measurement control components, glass industry **2017 onwards**



Half Year Results – Overview



	Half Year Results		Full Year Results		
(\$m)	1H18	1H17	2017	2016	2015
Sales revenue	12.1	10.5	21.5	21.0	20.5
EBITDA	1.2	0.9	1.7	3.0	4.1
Profit before tax	0.7	0.5	1.0	2.4	3.6
Acquisition costs	0.2	0.0	0.1	0.2	0.3
Platinum Division expansion costs	0.4	0.6	1.1	0.5	-
Underlying profit before tax	1.3	1.1	2.2	3.0	3.9
Net profit after tax	0.53	0.37	0.8	1.5	2.6
Earnings per share (cents)	0.4	0.3	0.6	1.2	2.0
Weighted average no. of shares	133,825,803	133,825,803	133,825,803	133,126,318	132,157,097
Dividends (cents per share)	0.0	0.0	0.24	0.5	1.2
Dividend payout ratio			40%	43%	60%

Balance Sheet



(\$m)	1H18	2H17	Change
Cash and cash equivalents	1.5	0.8	78%
Trade and other receivables	3.7	4.6	(20%)
Inventories	5.9	4.9	22%
Other assets	0.4	0.5	(34%)
Property, plant and equipment	8.2	7.2	14%
Intangible assets	16.0	16.0	1%
Deferred tax asset	0.7	0.7	(3%)
Total assets	36.4	34.7	5%
Trade and payables	2.6	2.4	10%
Debt (short term)	1.4	0.1	2430%
Debt (long-term)	1.0	1.2	(15%)
Deferred tax liability	0.3	0.3	3%
Total liabilities	5.3	4.0	33%
Total equity	31.1	30.7	1%

- Short term debt: \$1.1m building loan due for renewal in November after initial three year term
- \$1.2m new equipment loan for precious metals factory expansion. Includes \$0.5m cash refunded to XRFS for 40% deposit paid to supplier with our PO
- Inventories up: \$0.4m precious metals loan classified as on-balance sheet and \$0.3m stock for capital equipment projects to be invoiced in early 2H18


Consumables



(\$m)	1H18	2H17	1H17
Sales revenue	4.1	3.7	3.2
Change in %	13%	13%	4%
NPBT	1.0	0.8	0.9
Change in %	24%	(6%)	9%
Margin %	25%	23%	28%

Overview for 1H18:

- Revenue up 13% on 2H17
- NPBT up 24% on 2H17
- Strong sales activity driven by the mining sector globally
- Transfer of Scancia manufacturing plant to Perth




Precious Metals



(\$m)	1H18	2H17	1H17
Sales revenue	5.2	4.6	4.3
Change in %	12%	6%	(9%)

NPBT	(0.1)	(0.2)	(0.4)
Change in %	(65%)	(44%)	
Margin %	(1%)	(4%)	(8%)



1H13 2H13 1H14 2H14 1H15 2H15 1H16 2H16 1H17 2H17 1H18

Net Profit Before Tax (\$'000)

Overview for 1H18:


- Revenue up 12% on 2H17
- LBT down 65% on 2H17
- Germany office revenue up 88% to \$784k for 1H18 vs \$416k 2H17
- \$1.2m new equipment commissioned to expand production capability and product range
- New glass industry customers acquired
- First order delivered for new aerospace customer

Capital Equipment



(\$m)	1H18	2H17	1H17
Sales revenue	3.3	3.2	3.1
Change in %	3%	2%	(23%)

NPBT	0.1	0.1	0
Change in %	(24%)	496%	(108%)
Margin %	2%	3%	(1%)



1H13 2H13 1H14 2H14 1H15 2H15 1H16 2H16 1H17 2H17 1H18

Net Profit Before Tax (\$'000)

Overview for 1H18:

- Revenue up 3% on 2H17
- NPBT down 24% on 2H17
- Strong level of orders on hand across all product types
- Launch of Phoenix GO gas only fusion machine



Outlook



- Revenue growth of Germany office expected to continue throughout 2H18. Targeting a break-even result on a monthly basis for the office this calendar year
- Continue expanding our portfolio of precious metals products and capabilities in the Melbourne factory
- Strong order book for capital equipment products, in particular electric fusion machines. Additional revenue expected from Phoenix GO and xrWeigh product lines
- Addition of Scancia flux product line to main chemicals factory in Perth



Disclaimer



No responsibility for contents of Investor Presentation

- •To the maximum extent permitted by law, XRF Scientific Limited and representatives:
- •make no representation, warranty or undertaking, express or implied, as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient;
- •accept no responsibility or liability as to the adequacy, accuracy, completeness or reasonableness of this Investor Presentation or any other written or verbal communication transmitted or made available to any recipient; and
- accept no responsibility for any errors or omissions from this Investor Presentation whether arising out of negligence or otherwise.

Accuracy of projections and forecasts

•This Investor Presentation includes certain statements, opinions, estimates, projections and forward looking statements with respect to the expected future performance of XRF Scientific Limited. These statements are based on, and are made subject to, certain assumptions which may not prove to be correct or appropriate. Actual results may be materially affected by changes in economic and other circumstances which may be beyond the control of XRF Scientific Limited. Except to the extent implied by law, no representations or warranties are made by XRF Scientific Limited, its advisers or representatives as to the validity, certainty or completeness of any of the assumptions or the accuracy or completeness of the forward looking statements or that any such statement should or will be achieved. The forward looking statements should not be relied on as an indication of future value or for any other purpose.

No offer to sell or invitation to buy

•This Investor Presentation does not, and should not be considered to, constitute or form part of any offer to sell, or solicitation of an offer to buy, any shares in XRF Scientific Limited, and no part of this Investor Presentation forms the basis of any contract or commitment whatsoever with any person.

This Investor Presentation does not constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is not permitted under applicable law. Distribution of this Investor Presentation in or from certain jurisdictions may be restricted or prohibited by law. Recipients must inform themselves of and comply with all restrictions or prohibitions in such jurisdictions. Neither XRF Scientific Limited, its advisers or representatives accept any liability to any person in relation to the distribution or possession of this Investor Presentation from or in any jurisdiction.